Ketone Ester Co-administration Blunts Semaglutide-Induced Skeletal Muscle Loss in Obese Mice
Background
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide are highly effective for obesity treatment, a significant concern is the accompanying loss of skeletal muscle mass. Up to 45% of the weight reduction can be lean mass, leading to sarcopenia, which impairs mobility, metabolic regulation, and long-term health. This muscle loss can undermine the overall benefits of weight management. Understanding and mitigating this adverse effect is crucial to optimize GLP-1RA therapies and ensure healthier, more sustainable weight loss outcomes for patients.
Study Design
Researchers investigated whether oral ketone ester supplementation could prevent semaglutide-induced muscle loss in obese, glucose-intolerant mice. Animals were divided into three groups: vehicle, semaglutide monotherapy, or semaglutide plus a β-hydroxybutyrate-generating ketone ester. Treatments were administered for three weeks. Key endpoints included longitudinal assessment of body composition, muscle strength, and endurance. Molecular mechanisms were explored by analyzing mitochondrial and atrophy-related gene expression in skeletal muscle samples using techniques like qPCR.
Results
Semaglutide monotherapy significantly reduced lean mass and impaired muscle strength in obese mice. This was accompanied by a suppression of mitochondrial gene expression and an elevation of atrophy-related genes in skeletal muscle samples. Crucially, co-administration with ketone ester preserved skeletal muscle mass and function, demonstrating a protective effect. This benefit occurred without compromising the primary goal of fat loss, indicating a targeted intervention. Mechanistically, ketone ester co-treatment prevented the semaglutide-induced changes in both mitochondrial and atrophy-related gene expression. This suggests that impaired mitochondrial function and altered ketone metabolism may contribute to GLP-1RA-induced muscle loss.
Ketone ester supplementation maintained muscle mass and performance during semaglutide-driven weight loss, effectively counteracting its sarcopenia-promoting effects.
Key Findings
- Semaglutide monotherapy reduced lean mass and impaired muscle strength in obese, glucose-intolerant mice.
- Semaglutide suppressed mitochondrial gene expression and elevated atrophy-related genes in skeletal muscle.
- Co-administration of ketone ester preserved skeletal muscle mass and function during semaglutide treatment.
- Ketone ester co-treatment did not compromise semaglutide's fat loss efficacy.
- Ketone esters prevented semaglutide-induced changes in mitochondrial and atrophy-related gene expression.
Why It Matters
This preclinical study offers a promising strategy for individuals using GLP-1RAs like semaglutide to manage obesity, particularly for those concerned about muscle loss. Co-administering ketone esters could allow for more beneficial weight loss, preserving crucial muscle mass and function without hindering fat reduction. This could translate to improved long-term metabolic health, better mobility, and a higher quality of life for patients. While currently preclinical, these findings suggest a potential stacking protocol where ketone esters are integrated with GLP-1RA therapy, warranting clinical trials to assess its translational potential and develop a usable protocol for human application.
semaglutide
ketone-ester
obesity
muscle-loss
sarcopenia
preclinical-animal